Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human IMGN151 monotherapy in recurrent gynecologic cancers
2023-506842-22-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of opugotamig olatansine in endometrial cancer (EC), epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and 2 more (7 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability and Recommended monotherapy dose. Planned start Aug 2024; status: authorised.
02
Drugs
opugotamig olatansine
03
Conditions
endometrial cancer (EC)epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2023-506842-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506842-22-00.